First Citizens Bank & Trust Co. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 9.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 165,042 shares of the biopharmaceutical company’s stock after acquiring an additional 13,922 shares during the quarter. Pfizer accounts for 0.9% of First Citizens Bank & Trust Co.’s holdings, making the stock its 22nd biggest position. First Citizens Bank & Trust Co.’s holdings in Pfizer were worth $7,204,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in PFE. Home Federal Bank of Tennessee boosted its stake in shares of Pfizer by 0.8% during the fourth quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock valued at $1,297,000 after purchasing an additional 249 shares in the last quarter. Advocacy Wealth Management Services LLC boosted its stake in shares of Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 258 shares in the last quarter. Capital City Trust Co. FL boosted its stake in shares of Pfizer by 6.9% during the fourth quarter. Capital City Trust Co. FL now owns 5,139 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 330 shares in the last quarter. Acropolis Investment Management LLC lifted its stake in shares of Pfizer by 3.6% in the fourth quarter. Acropolis Investment Management LLC now owns 10,149 shares of the biopharmaceutical company’s stock worth $443,000 after acquiring an additional 350 shares during the period. Finally, West Oak Capital LLC lifted its stake in shares of Pfizer by 1.3% in the fourth quarter. West Oak Capital LLC now owns 27,761 shares of the biopharmaceutical company’s stock worth $1,212,000 after acquiring an additional 360 shares during the period. 69.49% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Mikael Dolsten sold 149,553 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the completion of the sale, the insider now owns 390,097 shares in the company, valued at $16,988,724.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Douglas M. Lankler sold 38,800 shares of the company’s stock in a transaction on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total value of $1,598,172.00. Following the sale, the executive vice president now owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 332,526 shares of company stock valued at $14,346,539. Corporate insiders own 0.09% of the company’s stock.
Shares of NYSE PFE traded down $0.05 during midday trading on Wednesday, hitting $39.37. 20,109,900 shares of the stock traded hands, compared to its average volume of 24,662,238. The company has a market cap of $235.26 billion, a price-to-earnings ratio of 13.12, a P/E/G ratio of 2.37 and a beta of 0.75. Pfizer Inc. has a one year low of $34.37 and a one year high of $46.47. The company has a quick ratio of 1.33, a current ratio of 1.57 and a debt-to-equity ratio of 0.52.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.01. The firm had revenue of $13.98 billion during the quarter, compared to the consensus estimate of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The company’s quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.62 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.86 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This story was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/24/first-citizens-bank-trust-co-boosts-position-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: How is diluted EPS different from basic EPS?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.